Gilteritinib (Xospata)

Mechanism of action

Tyrosine kinase inhibitor of FLT3, AXL, and ALK

Diseases for which it is used

• FLT3+ AML

History of changes in FDA indication

• 11/28/2018: Initial FDA approval for treatment of adult patients who have relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation as detected by an FDA-approved test. (Based on ADMIRAL)

Patient Drug Information

• Gilteritinib (Xospata) Package Insert

Also known as

• Code name: ASP2215
• Brand name: Xospata